Navigation Links
Omni Bio Pharmaceutical Intends to Expand Type 1 Diabetes Trial to 50 Patients
Date:2/28/2011

ase are forward-looking statements that reflect management's current views and expectations with respect to future events, including the expansion and commencement of clinical trials and the outcome and expenses of such trials.  These forward-looking statements are not a guarantee of future events and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual events to differ materially from those expressed or implied by the statements.  These risks and uncertainties are based on a number of factors, including but not limited to receipt of adequate funding to expand and commence clinical trials; receipt of applicable regulatory approvals for clinical trials, the risks related to the ownership and enforceability of our licensed intellectual property necessary to conduct the clinical trials and the business risks disclosed in our SEC filings, especially the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2010.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Omni Bio Pharmaceutical, Inc.

Hayden IR  Edward C. Larkin, Chief Operating Officer

Brett Maas, Managing Partner(720) 488-4708

(646) 536-7331Email: brett@haydenir.com   - or -Cameron Donahue, Partner(651) 653-1854Email: cameron@haydenir.com
'/>"/>

SOURCE Omni Bio Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...   HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the ... revenue of $73.6 million for the quarter ended ... the quarter ended June 30, 2014.  Currency fluctuations ... nine percentage points, during the three months ended ...
(Date:7/30/2015)... -- , Net Sales of $1.17 billion represent a ... an increase of 5.7% constant currency , Reported net ... adjusted earnings per share were $1.59, an increase of 0.6% ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... 30, 2015.  The Company reported second quarter net sales of ...
(Date:7/30/2015)... Maine, July 30, 2015  IDEXX Laboratories, Inc. (NASDAQ: ... quarter of 2015 of $413 million, an increase of ... the strengthening of the US dollar reduced reported revenue ... for the quarter was 11%, supported by strong growth ... per diluted share ("EPS") was $0.60 for the quarter, ...
Breaking Medicine Technology:HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 2Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 3Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 4Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 5Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 6Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 7Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 8Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 9Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 10Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 11Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 12Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 13Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 14Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 15Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 16Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 17Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 18Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 19Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 20Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 21Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 22Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 23
... ASSERT Trial Presented at EULAR, BARCELONA, Spain, ... at the European League Against Rheumatism (EULAR),Annual ... with,ankylosing spondylitis (AS) who received REMICADE(R) (infliximab),over ... In addition, REMICADE-treated patients showed sustained,reductions in ...
... Biotech (OMX Nordic: ACTI) presented,pre-clinical results for ... (The,European League Against Rheumatism, <a target="_blank" href=,"http://www.eular.org/">www.eular.org ... pre-clinical data presented show that I-3D has ... an,experimental model for rheumatoid arthritis (RA)", commented ...
Cached Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2
(Date:7/30/2015)... Washington, DC (PRWEB) , ... July 30, 2015 ... ... top global managers at multinational organizations and NGO’s, according to a new survey ... today, also shows that property damage and employee medical expenses represented the largest ...
(Date:7/30/2015)... ... , ... HEALTHCAREfirst , the leading provider of cloud-based software, services and ... a free webinar detailing the 2016 proposed rule from CMS for home health. , ... of Regulatory Affairs for the National Association for Home Care and Hospice (NAHC), and ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... and packaging services for consumer brands, recently completed a consolidation of all of ... Previously, the company operated out of two separate locations situated 11 miles apart. ...
(Date:7/29/2015)... ... 30, 2015 , ... Macro Wealth Management (MWM) Presidents have increased ... Lifetime program by encouraging their clients to donate their MWM planning fees to the ... McClellan and Tim Streid, who see charitable giving as an important part of financial ...
(Date:7/29/2015)... , ... July 29, 2015 , ... According to data ... Medicare Part D premium is expected to remain stable at $32.50, a figure far ... popular Part D program continues to be a bright spot in American health care. ...
Breaking Medicine News(10 mins):Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Smile for a Lifetime (S4L) Partners with Macro Wealth Management (MWM) Helping More Children Get Braces 2
... K. Bickel, director of the Center for Substance Abuse ... selected as the 2011 recipient of the American Psychological ... Association for Behavior Analysis International, the award recognizes individuals ... to awards chair Cythia Pietras, the award is being ...
... patients participate in clinical trials in part due to a ... published Feb. 11 in The Journal of the National ... trials are accepting participants, according to the National Cancer Institute ... participate in them. Prior studies suggest that most eligible patients ...
... News) -- When someone is trying to fake remorse, ... from one emotion to another very quickly, and speak ... could prove valuable to judges and parole board members, ... and parole release decisions, according to the study authors. ...
... DALLAS Feb. 14, 2011 UT Southwestern ... technology to diagnose Alzheimer,s disease from blood samples ... technology, which uses synthetic molecules to seek out ... eventually in the development of specific biomarkers for ...
... Dennis Thompson HealthDay Reporter , FRIDAY, Feb. 11(HealthDay ... carrying around the raw materials to save at least one ... blood, bone marrow and even the stem cells contained in ... people afflicted with terrible diseases, health officials say. But ...
... disease with a naturally present brain chemical signal ... mechanisms of the disease and open a future ... the University of South Florida Department Neurosurgery and ... Administration Hospital, Tampa. Their findings are published ...
Cached Medicine News:Health News:Brain researcher recognized for contributions to understanding, treatment of drug dependence 2Health News:Few physicians refer patients to cancer clinical trials 2Health News:Few physicians refer patients to cancer clinical trials 3Health News:Clues May Reveal When a Person Is Faking Remorse 2Health News:Preliminary new blood test to detect Alzheimer's disease uncovered 2Health News:Need for Blood and Organ Donors Continues to Grow 2Health News:Need for Blood and Organ Donors Continues to Grow 3Health News:Need for Blood and Organ Donors Continues to Grow 4Health News:Need for Blood and Organ Donors Continues to Grow 5Health News:Naturally occurring brain signaling chemical may be useful in understanding Parkinson's 2
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... ELISA test for Clostridium difficile antigen that ... sensitivity. That means the laboratory can quickly, ... negatives - which can represent up to ... the organism - and be sure that ...
... Difficile Tox A/B II is a second-generation rapid ... A and B in fecal specimens. The test ... results detecting not only the more common toxin ... A-/B+. It's easy to perform, produces no indeterminates ...
... now offers the first and only ... and monitoring of bladder cancer patients. ... quantitative microplate enzyme immunoassay that detects ... the urine of patients with bladder ...
Medicine Products: